Must Reads: Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck

Sichuan Kelun-Biotech will partner seven preclinical antibody-drug conjugate assets with Merck in a deal that pays Kelun

Must Reads Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck  Sichuan Kelun-Biotech will partner seven preclinical antibody-drug conjugate assets with Merck in a deal that pays Kelun-Biotech $175 million upfront ... Continue Reading FEATURED: Get a year of Premium for $39 Make 2023 your best year yet! Seeking Alpha Premium empowers your investing with analysis of just about every stock and ETF. Join now at the incredibly low price of $39 for your first year to experience its value for yourself. Go Premium Now PFFA: Leverage Hits Returns Again PFFA is one of the more popular actively managed preferred share ETFs. While the fund has shown moments of brilliance, overall performance has been po... Continue Reading T. Rowe Price: A 4.4% Yielding Dividend Growth Christmas Present For 2023 T. Rowe Price has had a rough year in 2022 with shares down over 40% YTD. Despite a weaker environment this year, the margin profile has remained attr... Continue Reading NGL Energy: Preferreds Get An Upgrade On our last call on NGL Energy, we upgraded the common shares to a hold, and left the preferreds on a Sell rating. They have lost an additional 25% va... Continue Reading 'Winter Chill' Dims Holiday Cheer U.S. equity markets declined for a third-straight week as benchmark interest rates surged after the advance of a $1.7 trillion federal spending packag... Continue Reading Download the Seeking Alpha App! Like Must Reads? Try our other newsletters as well. This email was sent to you because you signed up to receive Must Reads. If you do not want to receive Must Reads emails, click here to unsubscribe. Sent by Seeking Alpha, 234 5th Ave, 5th floor, New York, NY 10001